The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Procrit Market Increase Between 2026 And 2030?
The expansion observed during the historic period stemmed from a growing occurrence of chronic kidney disease, an escalation in chemotherapy-induced anemia instances, the integration of biologic treatments for anemia, an increase in the number of dialysis treatment centers, and enhanced availability of prescription anemia medications.
The anticipated growth during the forecast period is due to a heightened focus on personalized anemia care, the increasing acceptance of biosimilar alternatives, the expansion of chronic illness treatment initiatives, a stronger emphasis on improving patient quality of life, and augmented investments in optimizing biologic drugs. Major developments expected in this period encompass the rising utilization of erythropoiesis-stimulating agents, an escalating need for anemia management therapies, the broadening of supportive care treatments in oncology, a greater drive to reduce blood transfusions, and more rigorous monitoring of chronic anemia conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20189&type=smp
What Market Drivers Are Helping Shape The Procrit Market Expansion?
The anticipated growth in anemia cases is expected to propel the Procrit market forward. Anemia is a medical condition marked by a deficit of healthy red blood cells or hemoglobin, leading to diminished oxygen delivery to the body’s tissues. The rise in anemia incidence stems from factors such as a growing global burden of chronic conditions like kidney failure, cancer, and inflammatory disorders, alongside inadequate nutrition contributing to iron, vitamin B12, and folate deficiencies. Procrit (epoetin alfa) is utilized to address anemia caused by chronic kidney disease, chemotherapy, or specific HIV treatments. It functions by encouraging the production of red blood cells, thereby decreasing the necessity for blood transfusions in patients with low hemoglobin levels. For example, in December 2024, data from the National Center for Health Statistics, a US-based government agency, showed that the prevalence of anemia among individuals aged 2 years and older in 2023 had increased by 9.3% compared to 2021. Consequently, the increasing prevalence of anemia acts as a key driver for the Procrit market. The growing occurrence of chronic kidney diseases is projected to advance the Procrit market in the coming years. Chronic kidney disease describes a condition where the kidneys gradually lose their capacity to filter waste products from the blood. The increase in chronic kidney disease cases is attributed to an aging global population, rising obesity rates, and lifestyle choices combined with environmental exposures. Procrit (epoetin alfa) is administered to patients with chronic kidney disease to manage anemia by stimulating red blood cell production, helping to sustain adequate hemoglobin levels, and diminishing the requirement for blood transfusions. For instance, in June 2023, a report from Kidney Research UK, a UK-based non-profit organization, indicated that approximately 7.2 million people in the UK are currently living with chronic kidney disease, which is more than 10% of the population. Among these, 3.25 million are in advanced stages, while an additional 3.9 million are in early stages. By 2033, the number of individuals affected by chronic kidney disease is anticipated to climb to 7.61 million. Therefore, the rise in the prevalence of chronic kidney diseases is a significant driver for the Procrit market.
How Is Segment Classification Applied In The Procrit Market?
The procrit market covered in this report is segmented –
1) By Indications: Chronic Kidney Diseases, Human Immunodeficiency Virus (HIV) Infection, Chemotherapy
2) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Retail Pharmacies
3) By End Users: Hospitals, Outpatient Clinics, Home Care
Which Companies Form The Competitive Landscape Of The Procrit Market?
Major companies operating in the procrit market are Amgen Inc.
Access The Complete Procrit Market Report:
https://www.thebusinessresearchcompany.com/report/procrit-global-market-report
Which Area Represents The Largest Portion Of The Procrit Market?
North America was the largest region in the procrit market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the procrit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model